News coverage about Harvard Bioscience (NASDAQ:HBIO) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Harvard Bioscience earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 88 out of 100, meaning that recent news coverage is very likely to have an effect on the company’s share price in the immediate future.
Several brokerages recently commented on HBIO. Zacks Investment Research lowered shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Friday. ValuEngine cut shares of Harvard Bioscience from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd.
Harvard Bioscience (HBIO) opened at 2.35 on Tuesday. The stock’s 50 day moving average is $2.51 and its 200 day moving average is $2.67. Harvard Bioscience has a 12 month low of $2.25 and a 12 month high of $3.30. The firm’s market cap is $81.35 million.
In related news, CEO Jeffrey Duchemin bought 22,000 shares of the company’s stock in a transaction dated Monday, June 12th. The stock was acquired at an average cost of $2.76 per share, with a total value of $60,720.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Earl R. Lewis bought 12,238 shares of the company’s stock in a transaction dated Thursday, May 25th. The stock was bought at an average cost of $2.35 per share, with a total value of $28,759.30. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 52,950 shares of company stock valued at $135,275. Insiders own 8.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Harvard Bioscience (HBIO) Getting Somewhat Favorable News Coverage, Report Finds” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thestockobserver.com/2017/07/18/somewhat-favorable-press-coverage-very-likely-to-affect-harvard-bioscience-hbio-share-price-updated-updated-updated.html.
About Harvard Bioscience
Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.
Receive News & Ratings for Harvard Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.